Skip to content

Personalized Risk Prediction in Coronary Artery Disease

Personalized Risk Prediction in Coronary Artery Disease - PRECAD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00020960
Enrollment
1400
Registered
2020-04-20
Start date
2019-03-17
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease I25

Interventions

Group 1: We aim to improve personalized risk prediction regarding coronary artery disease using big data. A cohort of n=1,400 patients undergoing consecutively coronary angiography in 2005/2006 will b

Sponsors

Deutsches Herzzentrum München der Technischen Universität
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients 18 years of age or older 2. Informed, written consent by the patient 3. Coronary angiogram showing one of the following: - coronary three vessel disease, or - coronary two vessel disease, or - exclusion of relevant coronary lesions

Exclusion criteria

Exclusion criteria: 1. Acute myocardial infarction 2. Cardiogenic shock, haemodynamic instability 3. Active bleeding or clinically important anemia (i.e. <7g/dl) 4. Participation in an investigational drug or device study in the last 30 days 5. Pregnancy or lactation 6. Any other severe comorbidity such as active cancer with life expectancy less than 12 months.

Design outcomes

Primary

MeasureTime frame
All-cause mortality

Secondary

MeasureTime frame
myocardial infarction, stroke, MACE (all-cause mortality, myocardial infarction, stroke), revascularization, severe bleeding, risk prediction, prognostic values

Countries

Germany

Contacts

Public ContactMoritz von Scheidt

Deutsches Herzzentrum München der Technischen Universität

moritz.scheidt@tum.de+49-89-1218-2849

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026